Objectives-To investigate the presence of antibodies to HTLV
cycles, 4 mmolIl MgCl2) in a 2-5% agarose gel visualised using ethidium bromide 0-5 ,ug/ml. The presence of exogenous retroviruses was assessed using sense and antisense primers: SK43 (Cetus, 5'-CGGATACCCAGTCTAC-GTGT-3') and SK44 (Cetus, 5'-GAGCCGA-TAACGCGTCCATCG-3') for HTLV-I tax, and SK100 (5'-ATCAAGCAGCCATGCA-AAT-3') and SK104 (5'-CCTTTGGTC-CTTGTCTTATGTC-3') for HIV-1 gag region (conditions: 950 for one minute, 550 for one minute, 720 for two minutes, 35 
Results

SEROLOGICAL EVALUATION OF RHEUMATOLOGICAL PATIENTS
Enzyme linked immunosorbent assay-In the HTLV-I ELISA, four of 30 RA sera were considered positive, giving optical density values greater than the cut off value (figure); three were from male patients and one from a female. Of 13 PM/DM patients, three were positive: two white (male and female) and one West Indian (female). In our study all 14 pSS sera were negative and two of five SLE sera were considered positive; both were white. Within groups, there was no difference in mean age and disease duration for those considered positive in this assay system. Thirty normal sera were also negative in the HTLV-I ELISA; in the disease control group, two of 80 patients were considered positive: one 73 year old male bacterial endocarditis patient and one 79 year old male patient with osteoarthritis, both white. Overall the data showed no significant association of HTLV-I ELISA reactivity in rheumatoid arthritis patients in relation to the disease control group (table 2) . Levels of significance were only achieved for HTLV-I in PM/DM patients and SLE patients, in relation to inflammatory diseases (Crohn's and bacterial endocarditis) or patients with osteoarthritis. There was no association of retroviral antibodies and rheumatoid factor. Sera were also tested against recombinant HIV-1 p24. However, in this assay system only one RA serum and one pSS serum (derived from white subjects), and two control group sera revealed that none of the pSS sera was positive for HTLV-I and only one was positive for HIV-1 p24 in ELISA. In an HTLV-I endemic area of Japan (prevalence of serum antibodies in adults over 40 years, 10-25%), 36% of pSS patients were positive for HTLV-I although clinical comparisons between HTLV-positive/ negative pSS patients showed no significant difference.8 In contrast, a study in a non-HTLV-I-endemic area showed no reactivity with either HTLV-I structural proteins or envelope proteins of HIV-1, but did find antibodies to HIV-1 p24 in 14 (30%) of 47 patients with pSS.24 It was possible that optical density values above the cut off in HTLV-I ELISA may have been attributable to reactivity with non-HTLV-I antigens in the lysate. Thus validation of results was required in Western blotting. Evidently none of the sera in our study was HTLV-I positive according to accepted criteria (reactivity with antigens p21, p19, p24, p28, p38, gp46). A study using Western blotting has shown that in SLE, 36% of patients have serum antibodies to HIV-1 p24 (compared with <1% in normal subjects)25 and do not have antibodies to HTLV-I; the latter result was also confirmed in a study using sera from 36 SLE patients. 26 In our study, Western blotting revealed weak reactivity against a number of retroviral antigens: p2i, p19, p24, p38 and gp46 (reactivity against p42 tax was noted in the majority of samples, including normal: this observation was consistent with the kit specification protocol). These results may be explained either by the presence of a retrovirus or by molecular mimicry.27 The latter may occur when an organism shares sequence or amino acid homology with a normal cellular component, for example HIV gp4l and HLA class IL. 28 While it has been suggested that polyclonal B cell activation may account for the presence of cross reactive antibodies, it is apparent that pokeweed mitogen stimulation of HIV seronegative patients has produced only antibodies reactive with envelope glycoproteins gp 120, gp 120 and p66.29 An alternative explanation is the presence of rheumatoid factor, which is a common problem causing false positivity in assay systems. However in our study, there was no correlation between the presence of rheumatoid factor and ELISA reactivity. Furthermore, not all rheumatoid factor positive sera exhibited reactivity in Western blotting.
Previous molecular biology investigations have focused on nucleotide sequence analysis of SLE plasma DNA which revealed 80% sequence homology with the gag-pol overlap region of HIV-1.3O Furthermore an exocrinopathy resembling pSS has been described in mice transgenic for the HTLV-I tax (transactivating) gene.3' In order to assess if a known exogenous retrovirus was involved we pursued a direct approach using PCR for HTLV and HIV on our cohort of patients. Intact DNA (validated using ,3-globin primers) from peripheral blood mononuclear cells was amplified using primers for HTLV-I tax and HIV-1 gag regions. However, examination of patients with cross reactive antibodies to retroviral products proved negative. 
